Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors
The primary purpose of this study is to assess the effectiveness of zanzalintinib compared to everolimus in participants with previously treated, unresectable, locally advanced or metastatic neuroendocrine tumors.
Pancreatic Neuroendocrine Tumor (pNET)|Extra-Pancreatic Neuroendocrine Tumor (epNET)
DRUG: Zanzalintinib|DRUG: Everolimus
Progression-Free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors Version (RECIST) 1.1 as Assessed by Blinded Independent Central Review (BICR), Up to 48 months
PFS Per RECIST 1.1 as Assessed by Investigator, Up to 48 months|Objective Response Rate (ORR) Per RECIST 1.1 as Assessed by BICR and Investigator, Up to 48 months|Overall Survival (OS), Up to 60 months|Duration of Response (DOR) Per RECIST 1.1 as Assessed by BICR and Investigator, Up to 48 months|Disease Control Rate (DCR) Per RECIST 1.1 as Assessed by BICR and Investigator, Up to 48 months|Change From Baseline in Participant-Reported Global Health Status (GHS) and Disease-Related Symptoms as Assessed by European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLQ-C30) Score, Up to 48 months|Change From Baseline in Participant-Reported GHS and Disease-Related Symptoms as Assessed by EORTC Gastrointestinal Neuroendocrine Tumor module (QLQ-GI.NET21) Score, Up to 48 months|Number of Participants With Adverse Events, Up to 48 months
The primary purpose of this study is to assess the effectiveness of zanzalintinib compared to everolimus in participants with previously treated, unresectable, locally advanced or metastatic neuroendocrine tumors.